Clinical Research Division, Fred Hutch
Dr. Colleen Delaney is pioneering methods to make umbilical cord blood transplants more available and successful worldwide. Because it does not need to be as closely matched to the patient as bone marrow, cord blood offers an option to those thousands of blood cancer patients every year who can’t find a matched adult donor. Dr. Delaney developed a breakthrough method for multiplying the small number of stem and progenitor cells in each cord blood unit hundreds of times over in the lab. Her primary research focus is on developing these multiplied cells for use in the clinic. Her goal is to develop therapies that protect patients from severe side effects after cord blood transplant or intensive chemotherapy. Dr. Delaney was the founding director of the Hutch’s Cord Blood Program.
Associate Professor, Pediatric Hematology/Oncology
University of Washington
1985-1989 Wesleyan University, Middletown, CT-BA, Molecular Biology and Biochemistry with Honors
1989-1991 Oxford University, Christ Church College, Oxford, England -MSc, Social Research and Social Policy -Concentrations: Medical Sociology/Sociology of Education
1992-1996 Harvard Medical School, Boston, MA - M.D., June 1996
Cord blood transplant, Notch-mediated ex vivo expansion of cord blood progenitor cells for clinical application, hematopoietic stem cell regulation
Study Number: 2010
View more cord blood transplantation clinical trials.
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210.